Le Lézard
Classified in: Health, Science and technology
Subject: Filing

NANO-X IMAGING LTD Files 2021 Annual Report on Form 20-F


NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission ("SEC") on May 2, 2022. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.nanox.vision under "Financials" in the Investors section.

The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, at [email protected].

About Nanox

Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. The vision of Nanox is to increase the early detection of medical conditions that are discoverable by medical image technologies based on X-rays, which we believe is key to increasing early prevention and treatment, improving health outcomes, and, ultimately, saving lives. We are developing a holistic imaging solution, which includes the Nanox System, comprised of the Nanox.ARC using our novel MEMs X-ray source technology, and the Nanox.CLOUD, a companion cloud software, integrated with AI solutions and teleradiology services. Our vision is to increase early detection of medical conditions that are discoverable by X-ray by improving access to imaging, reducing imaging costs, and enhancing imaging efficiency, which we believe is key to increasing early prevention treatment, improving health outcomes and ultimately saving lives. For more information, please visit www.nanox.vision.


These press releases may also interest you

at 23:22
The global flow cytometry market  size is estimated to grow by USD 6038.44 million from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of about 13.12%  during the forecast period....

at 22:52
BioArctic AB's (publ) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous...

at 22:36
The global drug discovery outsourcing market  size is estimated to grow by USD 1.79 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  7.44%  during the forecast period. ...

at 22:30
On or around February 6, 2024, Hypertension-Nephrology Associates, P.C. ("the Practice") became aware it was the target of an extortion attack when an extortion note was found on its computer system. Upon discovery of the extortion note, the Practice...

at 22:17
Dr. Scott McMahon of Whole World Health Care is happy to announce the 2024 annual Surviving Mold-CIRSx Conference, set to be held May 16-19, 2024 at the Hyatt Regency, located at 2615 Preston Road in Frisco, Texas, a city near Dallas. CIRSx was...

at 20:16
PDS Health®, a leading U.S. provider of integrated healthcare support services, proudly announces its recognition as one of The Civic 50 honorees of 2024 by Points of Light, the world's largest nonprofit dedicated to accelerating people-powered...



News published on and distributed by: